Evidence map›Paper›PMID 39433724›Full record

ArticleJournal of natural medicines2025

Angelic acid triggers ferroptosis in colorectal cancer cells via targeting and impairing NRF2 protein stability.

Yongyi Cao, Yu Wang, Yueyang Li, Sihan Liu, Lizhe Wang, Li Zhou, Ting Zhu

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. NRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yongyi CaoDepartment of Oncology, Hefei First People's Hospital, The Third Affiliated Hospital of Anhui Medical University, 390 Huaihe Road, Hefei, 230071, Anhui, China.
Yu WangDepartment of Oncology, Hefei First People's Hospital, The Third Affiliated Hospital of Anhui Medical University, 390 Huaihe Road, Hefei, 230071, Anhui, China.
Yueyang LiDepartment of Oncology, Hefei First People's Hospital, The Third Affiliated Hospital of Anhui Medical University, 390 Huaihe Road, Hefei, 230071, Anhui, China.
Sihan LiuDepartment of Oncology, Hefei First People's Hospital, The Third Affiliated Hospital of Anhui Medical University, 390 Huaihe Road, Hefei, 230071, Anhui, China.
Lizhe WangDepartment of Oncology, Hefei First People's Hospital, The Third Affiliated Hospital of Anhui Medical University, 390 Huaihe Road, Hefei, 230071, Anhui, China.
Li ZhouDepartment of Oncology, Hefei First People's Hospital, The Third Affiliated Hospital of Anhui Medical University, 390 Huaihe Road, Hefei, 230071, Anhui, China.
Ting ZhuDepartment of Oncology, Hefei First People's Hospital, The Third Affiliated Hospital of Anhui Medical University, 390 Huaihe Road, Hefei, 230071, Anhui, China. ting9977@126.com.

Funding

Hefei Applied Medicine Program Hwk2023zd021the School Research Fund of Anhui Medical University 2023xkj110
6 · The paper itself

Abstract

Ferroptosis is a unique programmed cell death driven by iron-dependent phospholipid peroxidation. Tumor cells that escape from the conventional therapies appear more sensitive to ferroptosis. Therefore, it is extremely urgent to find safe and efficient active ingredients that induce ferroptosis in tumor cells. Herein, we identified that angelic acid, as a potent anti-tumor active ingredient in Angelica sinensis, profoundly sensitizes CRC cells to ferroptosis via a natural compound library screen. We revealed that angelic acid treatment is sufficient to predispose CRC cells to ferroptosis phenotype, evidenced by malondialdehyde (MDA) accumulation, lipid peroxidation, and upregulation of ferroptosis-associated markers CHAC1 and PTGS2, which is abolished by ferroptosis inhibitor Fer-1. Moreover, the results of network pharmacology showed that NRF2 is critical for angelic acid-mediated CRC cell ferroptosis. Mechanistically, angelic acid exerted its ferroptosis induction via directly binding and facilitating the degradation of NRF2. In addition, the syngeneic mouse models revealed that angelic acid boosts CRC cell sensitivity to ferroptosis inducer sulfasalazine with essentially no toxicity in vivo. Collectively, our findings highlighted a previously unrecognized anti-tumor mechanism of angelic acid and represented an appealing therapeutic strategy for CRC treatment.

Indexed as

Colorectal NeoplasmsFerroptosisNF-E2-Related Factor 2AnimalsCell Line, TumorHumansMiceProtein StabilityNFE2L2 protein, humanNF-E2-Related Factor 2Angelic acidColorectal cancerCompound library screenFerroptosisNRF2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.